Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates

Molecules - Switzerland
doi 10.3390/molecules201119664
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

Phase I Study of Chimeric Anti-Cd20 Monoclonal Antibody in Chinese Patients With CD20-positive Non-Hodgkin’s Lymphoma

Chinese Journal of Cancer Research
Cancer ResearchOncology
2016English

Targeted Alpha-Therapy Using [Bi-213]anti-Cd20 as Novel Treatment Option for Radio- And Chemoresistant Non-Hodgkin Lymphoma Cells

Oncotarget
Oncology
2013English

Antibody-Targeted Paclitaxel Loaded Nanoparticles for the Treatment of CD20+ B-Cell Lymphoma

Scientific Reports
Multidisciplinary
2017English

Peptide–drug Conjugates as Effective Prodrug Strategies for Targeted Delivery

Advanced Drug Delivery Reviews
Pharmaceutical Science
2017English

Improving the Treatment of Non-Hodgkin Lymphoma With Antibody-Targeted Radionuclides

Cancer
Cancer ResearchOncology
2010English

T Cell Immunity to Lymphoma Following Treatment With Anti-Cd40 Monoclonal Antibody

Journal of Immunology
AllergyImmunology
2002English

Treatment of Graves' Disease and Associated Ophthalmopathy With the Anti-Cd20 Monoclonal Antibody Rituximab: An Open Study

European Journal of Endocrinology
MedicineEndocrinologyMetabolismDiabetes
2007English

Characterization of Novel Murine Anti-Cd20 Monoclonal Antibodies and Their Comparison to 2B8 and C2B8 (Rituximab)

International Journal of Oncology
Cancer ResearchOncology
2007English

199. A Non-Depleting Anti-Cd4 Monoclonal Antibody Suppressed Antibody Responses and Enhanced Efficacy From Gene Therapy in Pompe Disease

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy